Related Experiment Video
Updated: Jun 17, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
Published on: September 1, 2023
Vaccine adjuvants: a priority for vaccine research
Ali M Harandi1, Donata Medaglini, Robin J Shattock
1Department of Microbiology & Immunology, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Medicinaregatan 7A, Goteborg, Sweden. ali.harandi@microbio.gu.se <ali.harandi@microbio.gu.se>
Abstract:
The workshop on vaccine adjuvants was held in July of 2009 at the European Commission in Brussels, with the goal of identifying key scientific priorities as they pertain to the development of effective vaccines against life-threatening diseases especially those associated with poverty, including HIV/AIDS, malaria and tuberculosis as well as neglected infectious diseases. On the basis of new advances in adjuvant research and related technology as well as potential challenges and roadblocks, six priorities were identified to accelerate development of improved or novel vaccine adjuvants for human use.
More Related Videos
Related Concept Videos
Vaccine Production
Vaccines
Vaccinations
Microorganisms in Medicine and Therapeutics
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Smallpox

